2 active not recruiting, 2 recruiting. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
Follow Recurrent Hairy Cell Leukemia: new trials by email Literature Review of Recurrent Hairy Cell Leukemia trials Research Report on Recurrent Hairy Cell Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2024-12-16 | 2026-09-09 |
| Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 44 | 2013-04-30 | 2026-11-12 |
| Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia Cladribine, Laboratory Biomarker Analysis, Rituximab - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 150 | 2004-06-10 | 2026-06-11 |
Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Leukemia (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4)
Biopsy (3) · Specimen Handling (3) · CT-P10 (2) · Cladribine (2) · Rituximab (2) · High-Energy Shock Waves (1) · Magnetic Resonance Spectroscopy (1) · Spinal Puncture (1) · ibrutinib (1) · tovorafenib (1) · venetoclax (1)
National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (1)
United States (4)
Farhad Ravandi-Kashani (1) · Kerry A Rogers (1) · Robert J Kreitman (1) · Seema A Bhat (1)
PMID 21821712, PMID 33754642, PMID 41980020
UM1CA186712 (2), N01CM00039 (1), P30CA016058 (1), U01CA076576 (1)